The activity of methicillin, oxacillin, vancomycin, imipenem and FK037 against 106 isolates of staphylococci was assessed using a microbroth dilution method with low (10 5 cfu/mL) and high (10 7 cfu/mL) inoculum sizes. Overall, FK037, an oxime-type cephem antibiotic, was as active as imipenem, but less active than vancomycin (MIC 90 Tel: 804-675-5000 ext. 4298; Fax: 804-675-5437.
Introduction
Infections and colonization with methicillin-resistant Staphylococcus aureus (MRSA) are increasingly being recognized in hospitals. In 1991, 29% of all S. aureus isolated in US hospitals were methicillin-resistant. 1 In addition, serious staphylococcal infections, such as endocarditis, continue to increase in prevalence. Up to 47.1% of all cases of community-acquired endocarditis are caused by S. aureus. 2 Vancomycin has been the antibiotic of choice in the treatment of MRSA infections because these organisms are resistant to -lactam antibiotics.
Resistance to -lactam antibiotics is attributed to the presence of a low-affinity penicillin protein (PBP 2a) which is encoded by the mecA gene. 3 Most isolates containing the mecA gene express their resistance in a heterotypic (or heterogeneous) fashion. These isolates contain several subpopulations of cells, each with different susceptibilities to methicillin. Whereas the majority of cells may be susceptible to methicillin, a small fraction (typically 1 in 10 4 to 1 in 10 7 ) will demonstrate high-level resistance to -lactam antibiotics. Heterogeneity leads to misleading results from antibiotic susceptibility testing and may be an explanation for the eventual failure of -lactam antibiotics in the treatment of infections due to MRSA. 4 Methicillin resistance may also be phenotypically expressed in a homotypic (or homogeneous) manner. Isolates contain a uniform population of cells which have a high level of resistance to methicillin. Although homotypic isolates of S. aureus are highly resistant to -lactam antibiotics, they comprise a small percentage of all isolates studied. 5 Several methods have been used to characterize the phenotypic expression of -lactam antibiotic resistance in staphylococci. Efficiency of plating (EOP) experiments, or population analysis profiles, are performed by inoculating known isolates of bacteria on agar plates containing increasing concentrations of antibiotics. 6 This analysis tests for the presence of resistant subpopulations which grow at high concentrations of antibiotic beyond the usual (or reported) MIC and may be predictors of antibiotic failure in the treatment of MRSA infections.
FK037 is a novel parenteral broad-spectrum cephalo-sporin antibiotic which is active against a number of staphylococcal species, including MRSA. Previously, FK037 has been shown to be active against MRSA with MIC 90 s ranging from 16 to 32 mg/L. [7] [8] [9] [10] The activity of FK037 was evaluated in vitro against staphylococci resistant to multiple antimicrobial agents and its activity was compared with that of other antistaphylococcal antibiotics. In addition, EOP was used to screen for subpopulations resistant to -lactam antibiotics and the activity of FK037 was compared with that of imipenem and vancomycin in rabbits with endocarditis caused by a homogenously resistant clinical MRSA isolate. Our results suggested that, surprisingly, FK037 can be as effective as vancomycin in vivo against a highly methicillin-resistant S. aureus isolate.
Materials and methods

Isolates
The staphylococcal isolates used in these studies were taken from the culture collections maintained at the 
Antibiotic susceptibility testing
The MICs of methicillin, oxacillin, vancomycin, imipenem and FK037 against 106 staphylococci were determined by the microdilution method in cation-supplemented MuellerHinton broth (Becton Dickinson, Cockeysville, MD, USA) plus 2% NaCl at a final inoculum of 1 10 5 cfu/mL (low inoculum) and 1 10 7 cfu/mL (high inoculum). The lowest concentration of antibiotic yielding no visible growth after incubation at 37°C for 24 h was taken as the MIC. The MBC was determined by subculturing 20 L (low inoculum) or 10 L (high inoculum) on to Mueller-Hinton agar (MHA; Becton Dickinson). The lowest antibiotic concentration yielding no growth on subculture after 24 h of incubation at 37°C was the MBC and represented the concentration of antibiotic that reduced viable numbers of organisms by 99.9%.
Efficiency of plating
To determine whether resistant subpopulations of cells were present, various staphylococci (12 MRSA, six MRSE and six S. haemolyticus) were inoculated on to MHA plates containing increasing concentrations of methicillin, imipenem or FK037. Inocula varied from 10 3 cfu/mL to 10 7 cfu/mL. The plates were incubated for 48 h at 37°C after which time cfu counts were tabulated and plotted against drug concentration.
Experimental endocarditis
Bacterial aortic valve endocarditis was established according to the technique of Perlman & Freedman. 11 Using aseptic technique, the right carotid arteries of 2-3 kg New Zealand white rabbits were exposed and cannulated with a 19-gauge polyethylene catheter. The catheter was advanced into the left ventricle until pulsations and resistance were felt. It was then sealed by ligatures and left in place for the duration of the experiment. At least 24 h following surgery, animals were challenged with 1 mL of a suspension containing 10 6 cfu of the test organisms through a marginal ear vein. Test organisms included VA117 (MSSA) and 27619 (a homotypic MRSA). Blood cultures were drawn 24 h following inoculation and animals were randomized to either a control group (no antibiotic therapy) or a treatment group. Animals were treated for 3 or 7 days with the following antibiotics: vancomycin hydrochloride (Eli Lilly, Indianapolis, IN, USA), 30 mg/kg iv every 12 h, nafcillin sodium (SmithKline Beecham, Worthington, UK), 100 mg/kg im every 6 h; imipenem with cilastatin (Merck, Rahway, NJ, USA), 30 mg/kg im every 6 h; or FK037 (R. W. Johnson Raritan, NJ, USA). FK037 was used in two im dosage regimens: 30 mg/kg every 12 h (low dose (LD) regimen) and 40 mg/kg every 6 h (high dose (HD) regimen).
Serum samples for antibiotic levels were drawn on the second day of treatment. On the fourth or eighth day, the animals were killed and autopsy was performed. The heart was removed aseptically and the aortic valve leaflets and left ventricle were exposed. Any vegetation material on the aortic leaflets, myocardium or around the catheter was resected and weighed. Vegetative material was homogenized in 1 mL of normal saline, serially diluted and inoculated on to blood agar plates. To test for the presence of resistant subpopulations, vegetations were also plated on to MHA plates containing imipenem or FK037 (5 mg/L). The frequency of resistance was expressed as the number of viable colonies on antibiotic-containing plates divided by the number of colonies seen on antibiotic-free blood agar plates. Spleens and kidneys from selected animals were removed at the time of autopsy and examined for the presence of metastatic infection. Specimens were examined grossly for infection and then weighed, homogenized, serially diluted and inoculated on blood agar plates as described. Bacterial titres were expressed as the log 10 cfu/g of vegetation or tissue.
Only animals with correct placement of the catheter, visible vegetations and positive blood cultures prior to the initiation of therapy were included in further analysis. A total of 103 animals underwent treatment of which 99 were included in subsequent analysis. For statistical analysis sterile vegetations were considered to contain 2 log 10 cfu/g, the limit of sensitivity of this assay. For purposes of quantitative analysis sterile tissue samples (spleens or kidneys) exhibited no growth at the lowest dilution and were assigned the value of the lowest detectable quantity of microorganisms among all samples, which was 0.7 log 10 for splenic tissue and 1.44 log 10 for kidney tissue.
The animal experiments were approved by the Institutional Animal Care and Use Committee of the Medical College of Virginia/McGuire Veterans Medical Center of the Virginia Commonwealth University.
Antibiotic assays
The concentration of each drug in serum was determined by the agar-diffusion method with Bacillus subtilis ATCC 6633 as the test organism. Sera were separated from blood components and frozen immediately at 70°C for assay at a later date.
Statistical analysis
Statistical analysis of bacterial titres in the vegetations and organ tissue was done by one-way analysis of variance (ANOVA). The Student-Newman-Keuls test was used to adjust for multiple comparisons. Comparison of rates of sterilization were made by the 2 test. Statistical significance was defined as a P value of 0.05.
Results
Antibiotic susceptibility testing
Results of antibiotic susceptibility testing are shown in Table I . Vancomycin was the most active antibiotic against 106 staphylococcal isolates, with an MIC 90 of 6.25 mg/L at the lower inoculum. For MRSA isolates, vancomycin was equivalent to imipenem and more active than FK037 (MIC 90 s: 6.25, 6.25 and 25 mg/L, respectively). FK037 inhibited 79% of MRSA isolates at 12.5 mg/L. S. haemolyticus isolates were highly resistant to all antibiotics tested except vancomycin. MSSA were susceptible to all antibiotics, with imipenem being the most active (MIC 90 0.2 mg/L). FK037 was more active than imipenem against MRSE isolates, but vancomycin was the most active (MIC 90 s: 12.5, 25 and 6.25 mg/L). FK037 inhibited 100% of MRSE isolates at a concentration of 12.5 mg/L. Sixteen of 33 MRSA isolates and 17 of 29 MRSE isolates appeared susceptible to oxacillin, but were resistant to methicillin, though this effect was not evident at the higher inoculum. 12 With the higher inoculum, a marked effect with imipenem was observed. In testing against all staphylococcal isolates, the MIC 90 increased four-fold for imipenem with the higher inoculum when compared with the lower inoculum (100 mg/L and 25 mg/L, respectively). Against MRSA isolates, the MIC 90 of imipenem increased eightfold with the high inoculum (50 mg/L and 6.25 mg/L, respectively). The higher inoculum had little effect on the MIC with FK037 or vancomycin, as MIC 90 increased one dilution overall.
Efficiency of plating
Isolates of staphylococci (12 MRSA, six MRSE and six S. haemolyticus) were evaluated in EOP experiments. For FK037 and imipenem, the presence of resistant subpopulations was defined as the growth of colonies at a concentration greater than twice the MBC. Resistant subpopulations were seen infrequently with FK037, with five of 24 isolates (21%) showing growth at more than twice the MBC. The five isolates with resistant subpopulations included three MRSA, one MRSE and one S. haemolyticus. In contrast, for imipenem 18 of 24 isolates (75%) gave resistant subpopulations, at twice the MBC. Results of EOP experiments with S. aureus 27619, the isolate used in the rabbit model of endocarditis, are presented in the Figure. Resistance to imipenem and FK037 was detected at concentrations of up to 100 mg/L, demonstrating a substantial number of resistant subpopulations in testing against both drugs.
Endocarditis
The mean peak serum concentration S.E. obtained on the second day of antibiotic therapy were: vancomycin, 69. The efficacy of antibiotic therapy in the rabbit model of aortic valve endocarditis is shown in Table III . FK037 was as active as imipenem and nafcillin in the treatment of endocarditis due to MSSA (VA117). All three antibiotics tested reduced the mean log 10 cfu/g valvular vegetation significantly when compared with control animals (P 0.05). Mean bacterial titres were reduced at least six-fold. In the therapy of infection with a homotypic MRSA (27619), vancomycin and FK037 were more active than imipenem and nafcillin in reducing mean bacterial counts in valvular vegetations (P 0.05). Nafcillin and imipenem, significantly reduced mean log 10 cfu/g of valvular vegetation when compared with control animals (P 0.05). No differences were noted between the two dosing regimens of FK037. There was no difference in effect between FK037 and vancomycin after 7 days of therapy, although both antibiotics significantly reduced the mean log 10 cfu/g vegetation after 7 days of therapy compared with the 3 day therapy regimen (P 0.0001). Both FK037 and vancomycin reduced bacterial titres more effectively after 7 days of therapy when compared with 3 days of therapy with similar rates of valve sterilization.
Following therapy with imipenem, vegetations from six of the nine animals cultured contained resistant organisms which amounted to 10% of the entire bacterial population (data not shown). In contrast, vegetations from only one of the animals treated with any dose of FK037 for 3 days contained resistant populations that comprised 10% of the entire bacterial population (P 0.053).
The efficacy of the antibiotics in reducing bacterial counts at other organs is shown in Table IV . FK037, imipenem, and vancomycin were the most active antibiotics in reducing mean log 10 cfu/g of organ tissue in spleens and kidneys. Although mean bacterial titres were not significantly different for imipenem, FK037 and vancomycin, rates of sterilization of these organs were significantly higher for FK037 and vancomycin than for imipenem (P 0.05). After therapy for 7 days with FK037, 100% of spleens and kidneys gave no growth on culture while only 88% were culture-negative following vancomycin (P 0.05). The duration of therapy had no effect on the rates of sterilization.
Discussion
FK037 is a new broad-spectrum, oxime-type cephem antibiotic which has been shown to have excellent activity against a wide variety of Gram-negative bacteria and Gram-positive bacteria such as Streptococcus pneumoniae, viridans streptococci, Streptococcus pyogenes, Streptococcus agalactiae and methicillin-sensitive staphylococci.
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FK037 has shown variable activity against the coagulasenegative and coagulase-positive methicillin-resistant staphylococci. The results of this study are consistent with recently published reports on the activity of FK037 against MRSA. 7, 9 Against MRSA isolates, FK037 had higher MIC 50 s and MIC 90 s than imipenem or vancomycin.
A profound effect was seen in the results of susceptibility testing with the use of the higher inoculum when evaluating both imipenem and FK037. Although 79% of MRSA isolates were susceptible to FK037 at a concentration of 12.5 mg/L, increasing the inoculum size to 10 7 cfu/mL decreased the percentage of susceptible isolates to 42%. Imipenem, showed the best activity against methicillinsusceptible staphylococci, but this activity was eliminated at the higher inoculum size and when comparing MBC results. The failure of FK037 and imipenem under more stringent conditions demonstrates the inadequacy of routine susceptibility testing in detecting resistant subpopulations.
The development of resistance due to the presence of resistant subpopulations may be a concern with FK037. In EOP experiments, 21% of staphylococci contained resistant subpopulations to FK037. In addition, the frequency of resistance was much higher than previously reported. 7 Against two MRSA isolates, Fu et al. 7 reported a frequency of resistance ranging from 2 10 5 and 2 10 9 for FK037. A high level of resistance to imipenem was also demonstrated using EOP. These studies emphasize the need to include measures to determine the phenotypic expression of resistance when evaluating potential therapeutic agents against methicillin-resistant staphylococci. Although imipenem appears very active against MRSA and MRSE in vitro, further testing has demonstrated that it is ineffective in vivo. 13 The use of EOP allows for the detection of resistant subpopulations which may in turn result in antibiotic failure.
FK037 was as active against MSSA as other -lactams tested in the experimental rabbit model of endocarditis. These results extend previous observations that cephalosporins, as well as -lactam antibiotics combined withlactamase inhibitors, may be effective treatment regimens for endocarditis due to MSSA. [14] [15] [16] [17] [18] [19] FK037, a new oxime-type fourth generation cephalosporin, is the first of its class to be evaluated in the endocarditis model. Cephalosporins have generally been avoided in the treatment of serious MRSA infections, although in-vitro testing has shown some activity. Clinical infections have occasionally responded to cephalosporins, but previous studies with cephalosporins in the experimental endocarditis model have had disappointing results. 4 In the studies reported here, FK037 was effective in the endocarditis model against a single MRSA strain and is the first instance where a cephalosporin antibiotic has been shown to be as active as vancomycin in the treatment of a serious infection due to MRSA. Recently, a new carbapenem, L695,256, was shown to be as active as vancomycin in a 23 Previously, the combination of -lactam with a -lactamase inhibitor has been shown to be effective in the treatment of endocarditis due to a 'borderline' oxacillin-resistant, -lactamase-hyperproducing strain of S. aureus. 15 The combination of amoxycillin with a -lactamase inhibitor (clavulanic acid) has also been reported to be effective in the treatment of endocarditis due to MRSA in rats. 20, 21 The success of FK037 may be related to several factors. First, the study isolate (S. aureus 27619) tested was highly susceptible (Table II) . Second, there was a low number of resistant subpopulations in cultured vegetation material in rabbits treated with FK037 when compared with rabbits treated with imipenem (mean percentage of resistant organisms 16.54% and 39.5%, respectively). Third, FK037 demonstrated favourable pharmacokinetics, with serum levels well above the MIC for each organism used in the rabbit model. Fourth, FK037 has been reported to have a high relative binding affinity for PBP 2a. 8 The importance of binding to PBP 2a as a measure of effectiveness against MRSA has been demonstrated repeatedly. 20, 22, 23 The successful treatment of MRSA endocarditis in the rat model with a combination of amoxycillin and clavulanic acid was explained, in part, by the high relative binding affinity of amoxycillin for PBP 2a compared with methicillin or oxacillin. 18 Amoxycillin is, in fact, ten times more avid in its binding to PBP 2a than methicillin. Similarly, Chambers has suggested that the high relative PBP 2a binding affinity of the carbapenem L695,256 was one explanation for its effectiveness in the rabbit model of MRSA endocarditis. Finally, FK037 has been shown to be highly resistant to hydrolysis by penicillinases and broad-spectrum cephalosporinases. 7 The success of FK037 in the rabbit model of aortic valve endocarditis was unexpected. Both MIC testing and EOP experiments indicated that a number of isolates contained subpopulations resistant to FK037. In particular, S. aureus 27619, the strain used in the endocarditis model, contained populations of cells resistant to FK037, at concentrations of up to 100 mg/L. Despite this, FK037 was as effective as vancomycin, and valvular vegetation material showed low rates of resistant subpopulations. In contrast, imipenem performed poorly in the rabbit model of endocarditis, yet showed a similar number of resistant subpopulations in EOP experiments.
The different pharmacokinetic properties of vancomycin, imipenem and FK037 exclusive of protein binding, are an unlikely explanation for the differences seen in the endocarditis model. Although imipenem has the shortest elimination half-life (1 h), it was given in the shortest dosing interval (6 h). In addition, the three drugs were given in the dosing intervals used in humans. Mean peak concentrations of imipenem were lower than those achieved by FK037, though they were comparable to levels achieved in humans 24 and those seen in previous rabbit models of endocarditis 23 and were well above the measured MIC for the test isolates (Table II) . These results suggest that the mere demonstration of resistant subpopulations in vitro by EOP may not correlate with in-vivo efficacy and that suppression of these subpopulations is a requirement for antibiotic effectiveness in in-vivo models of infection.
In conclusion, FK037 has shown activity against staphylococci including some methicillin-resistant isolates. It was also effective in the treatment of MRSA endocarditis in the rabbit model. Further studies may be warranted to determine its clinical utility in humans. These data would also indicate that cephalosporins may have a role in the treatment of serious MRSA infections. However, proper attention must be paid to the multiple factors required for the successful treatment of these infections when evaluating potential new therapeutic agents in the treatment of MRSA infections. Future testing of agents like FK037 should include screening for the presence of resistant subpopulations with EOP or populations analysis profiles and MIC testing using higher inocula. In-vivo efficacy should be evaluated in a stringent model of infection, such as the experimental animal model of endocarditis. In addition, measures of the relative binding affinities to PBP 2a may be useful in predicting therapeutic efficacy. However, until more information is available, vancomycin remains the drug of choice for serious MRSA infections.
